MediWound MDWD

NASDAQ MDWD

$13.73 -0.11 (-0.79%)

As of: Sep 10, 2026 · 3:59 PM EDT

Key Stats

Market Cap156.09 Mn

P/E-5.03

P/S13.16

Div. Yield0.00

Total Debt (Qtr)932,000.00

Revenue Growth (1y) (Qtr)-45.83

Add ratio to table…

About

MediWound Ltd. is a global leader in next generation enzymatic therapeutics focused on non surgical tissue repair. The company develops and commercializes biologics for wound and burn care, aiming to replace surgical debridement with enzymatic alternatives. MediWound generates revenue primarily from product sales of NexoBrid, royalties and milestone payments under its license agreement with Vericel for North America, and government funding for development programs such as…

Investment Thesis

▲ Bull case

MDWD is positioned to capitalize on a structural shift in the chronic wound care market driven by the recent Medicare Physician Fee Schedule change, which CMS stated will reduce spending on skin substitutes by nearly 90%, effectively translating to a $12 billion contraction from a $14 billion segment. This regulatory shift is expected to drop the U.S. chronic wound care market from $18 billion to $5.5 billion, disproportionately impacting legacy cellular tissue products (CTPs) that are now facing 60% year-over-year sales declines. As Barry Wolfenson explicitly noted, this creates a vacuum where differentiated products with higher regulatory approval—such as EscharEx, which is pursuing a BLA and is one of very few in late-stage development—will stand out. EscharEx’s mechanism, which achieves complete debridement in days rather than weeks, aligns perfectly with the industry’s move toward less invasive, early-course interventions validated by the U.S. expert consensus document in Wound Journal. Unlike CTPs, EscharEx does not rely on the now-eroded reimbursement loophole and instead enters a segment where legacy enzymatic debriders like SANTYL generate ~$400 million annually. With peak sales potential estimated at $831 million from venous leg ulcers and diabetic foot ulcers alone, the market expansion opportunity is substantial and underappreciated by investors focused solely on near-term enrollment delays in the VALUE study.
The expanding global collaboration network for EscharEx, now encompassing virtually all major advanced wound care players—including Medline, Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun, and MIMEDX—represents a hidden catalyst that management did not emphasize as a commercial de-risking factor. As Barry Wolfenson explained, these partnerships standardize trial design by using collaborators’ products as controls, minimizing variability and strengthening data integrity for regulatory submission. More critically, Medline’s provision of its Marathon skin protectant for the upcoming DFU Phase II study directly addresses periwound protection—a key gap in current standard of care—thereby enhancing EscharEx’s clinical utility and real-world adoption potential. This network is not merely academic; it creates a de facto pre-commercialization alliance where each partner has skin in the game, increasing the likelihood of rapid formulary access, co-promotion, and reimbursement support post-approval. The fact that these companies are investing resources into EscharEx trials signals deep confidence in its differentiation and market readiness, a point underweighted in current valuations that focus on cash burn and timelines.
NexoBrid’s long-term government demand is being significantly underestimated, particularly the strategic value of the new 10-year BARDA contract valued at up to $197 million, which builds on $138 million in prior BARDA and DoD funding. While management noted that revenue from this contract will begin in the second half of 2026, they did not highlight how this agreement transforms NexoBrid from a niche burn product into a cornerstone of national mass casualty preparedness. The contract explicitly supports next-generation manufacturing, room-temperature-stable formulation development, and potential blast trauma indication expansion—each of which opens multi-year, high-margin development services revenue streams beyond simple procurement. Furthermore, the recent adoption of national consensus guidelines in Japan and the U.K., alongside existing WHO-endorsed recommendations in Italy, Spain, Romania, and Poland, confirms a global standardization trend that management acknowledged but did not link to sustained international procurement pipelines. With the expanded manufacturing facility expected to complete EMA-recommended operational modifications by H2 2026 and FDA inspection slated for early 2027, MDWD is nearing the inflection point where NexoBrid can transition from government-funded development to recurring, scalable sales—both domestically and internationally—without relying on volatile commercial burn care adoption alone.

MDWD is positioned to capitalize on a structural shift in the chronic wound care market driven by the recent Medicare Physician Fee Schedule change, which CMS stated will reduce spending on skin substitutes by nearly 90%, effectively translating to a $12 billion contraction from a $14 billion segment. This regulatory shift is expected to drop the U.S. chronic wound care market from $18 billion to $5.5 billion, disproportionately impacting legacy cellular tissue products (CTPs) that are now facing 60% year-over-year sales declines. As Barry Wolfenson explicitly noted, this creates a vacuum where differentiated products with higher regulatory approval—such as EscharEx, which is pursuing a BLA and is one of very few in late-stage development—will stand out. EscharEx’s mechanism, which achieves complete debridement in days rather than weeks, aligns perfectly with the industry’s move toward less invasive, early-course interventions validated by the U.S. expert consensus document in Wound Journal. Unlike CTPs, EscharEx does not rely on the now-eroded reimbursement loophole and instead enters a segment where legacy enzymatic debriders like SANTYL generate ~$400 million annually. With peak sales potential estimated at $831 million from venous leg ulcers and diabetic foot ulcers alone, the market expansion opportunity is substantial and underappreciated by investors focused solely on near-term enrollment delays in the VALUE study.
The expanding global collaboration network for EscharEx, now encompassing virtually all major advanced wound care players—including Medline, Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun, and MIMEDX—represents a hidden catalyst that management did not emphasize as a commercial de-risking factor. As Barry Wolfenson explained, these partnerships standardize trial design by using collaborators’ products as controls, minimizing variability and strengthening data integrity for regulatory submission. More critically, Medline’s provision of its Marathon skin protectant for the upcoming DFU Phase II study directly addresses periwound protection—a key gap in current standard of care—thereby enhancing EscharEx’s clinical utility and real-world adoption potential. This network is not merely academic; it creates a de facto pre-commercialization alliance where each partner has skin in the game, increasing the likelihood of rapid formulary access, co-promotion, and reimbursement support post-approval. The fact that these companies are investing resources into EscharEx trials signals deep confidence in its differentiation and market readiness, a point underweighted in current valuations that focus on cash burn and timelines.
NexoBrid’s long-term government demand is being significantly underestimated, particularly the strategic value of the new 10-year BARDA contract valued at up to $197 million, which builds on $138 million in prior BARDA and DoD funding. While management noted that revenue from this contract will begin in the second half of 2026, they did not highlight how this agreement transforms NexoBrid from a niche burn product into a cornerstone of national mass casualty preparedness. The contract explicitly supports next-generation manufacturing, room-temperature-stable formulation development, and potential blast trauma indication expansion—each of which opens multi-year, high-margin development services revenue streams beyond simple procurement. Furthermore, the recent adoption of national consensus guidelines in Japan and the U.K., alongside existing WHO-endorsed recommendations in Italy, Spain, Romania, and Poland, confirms a global standardization trend that management acknowledged but did not link to sustained international procurement pipelines. With the expanded manufacturing facility expected to complete EMA-recommended operational modifications by H2 2026 and FDA inspection slated for early 2027, MDWD is nearing the inflection point where NexoBrid can transition from government-funded development to recurring, scalable sales—both domestically and internationally—without relying on volatile commercial burn care adoption alone.

▼ Bear case

MDWD’s near-term financial trajectory remains highly vulnerable to execution risks in the EscharEx VALUE study, despite management’s assurances that delays are purely operational. The company conceded that enrollment has progressed more gradually than anticipated due to protocol complexity—specifically, the requirement for daily wound assessment to determine the exact day of complete debridement, which creates significant participation barriers for older, medically complex venous leg ulcer patients. While patient assistance measures (hotel reimbursements, transportation) have been implemented, there is no evidence these have accelerated enrollment, and the assumption that enrollment will complete by end of Q1 2027 relies on maintaining current site performance without further disruptions. More concerning is the implicit acknowledgment that the study’s success hinges on excluding patients who would respond too well to placebo or too poorly to EscharEx—a subjective screening criterion that introduces bias risk and could undermine the validity of interim results. With R&D expenses rising to $5.2 million in Q1 2026 (up from $2.9 million YoY) driven by the VALUE study, any further delay would deepen cash burn, especially given the company’s limited cash runway of $45 million and Q1 operating cash outflow of $9.6 million. The market is not fully pricing in the probability that the study fails to meet its primary endpoint or requires additional enrollment, which would delay approval beyond 2027 and erode the near-term inflection point narrative.
The company’s 2026 revenue guidance of $24 million to $26 million is overly reliant on the timing of government-related development services and BARDA contract milestones, which remain opaque and execution-dependent. Management admitted they cannot disclose the revenue split between MediWound and Vericel under the BARDA contract, creating significant uncertainty about how much of the $197 million 10-year value will actually flow to MDWD. Furthermore, the guidance assumes revenue will be “weighted toward the second half” of 2026, yet Q1 2026 revenue was just $1.5 million—down from $4 million in Q1 2025—reflecting not only timing issues but also the fragility of relying on episodic government shipments postponed due to regional conflict. While Hani Luxenburg confirmed postponed shipments have been completed, this highlights the company’s vulnerability to geopolitical disruptions in its supply chain. The gross margin improvement to 21.9% (from 18.7%) was driven by a low-revenue base and does not reflect sustainable operational leverage; SG&A expenses rose to $3.6 million (from $3.1 million), and the adjusted EBITDA loss widened to $7 million (from $4 million). Without clear visibility into recurring commercial NexoBrid sales or EscharEx partnership milestones, the 2026 guidance appears aspirational rather than grounded in predictable, scalable revenue streams.
The commercialization path for EscharEx beyond venous leg ulcers remains speculative and under-substantiated, despite management’s expansion into diabetic foot ulcer (DFU) and pressure ulcer studies. While the company cited peer-reviewed consensus documents and conference presentations as validation, it provided no concrete data on efficacy, safety, or dosing regimens for these new indications during the Q&A. The planned Phase II DFU study and investigator-initiated pressure ulcer trial—both slated for H2 2026—are early-stage and carry high failure risk, particularly given the distinct pathophysiology of DFUs (e.g., neuropathy, ischemia) and pressure ulcers (e.g., sustained tissue compression). More critically, the company has not addressed how EscharEx will navigate reimbursement pathways for these indications, especially in light of the Medicare Physician Fee Schedule changes that are dismantling reimbursement for advanced wound care products broadly. Barry Wolfenson’s commentary on the $400 million SANTYL market and EscharEx’s potential to capture share assumes successful approval and adoption—but offers no insight into pricing strategy, payer negotiations, or formulary access challenges. Without clear differentiation in real-world effectiveness or cost-effectiveness data for DFU and pressure ulcers, the expansion narrative risks becoming a pipeline illusion that inflates long-term expectations without near-term de-risking, leaving investors exposed to binary outcomes tied to a single Phase III study in VLU.

MDWD’s near-term financial trajectory remains highly vulnerable to execution risks in the EscharEx VALUE study, despite management’s assurances that delays are purely operational. The company conceded that enrollment has progressed more gradually than anticipated due to protocol complexity—specifically, the requirement for daily wound assessment to determine the exact day of complete debridement, which creates significant participation barriers for older, medically complex venous leg ulcer patients. While patient assistance measures (hotel reimbursements, transportation) have been implemented, there is no evidence these have accelerated enrollment, and the assumption that enrollment will complete by end of Q1 2027 relies on maintaining current site performance without further disruptions. More concerning is the implicit acknowledgment that the study’s success hinges on excluding patients who would respond too well to placebo or too poorly to EscharEx—a subjective screening criterion that introduces bias risk and could undermine the validity of interim results. With R&D expenses rising to $5.2 million in Q1 2026 (up from $2.9 million YoY) driven by the VALUE study, any further delay would deepen cash burn, especially given the company’s limited cash runway of $45 million and Q1 operating cash outflow of $9.6 million. The market is not fully pricing in the probability that the study fails to meet its primary endpoint or requires additional enrollment, which would delay approval beyond 2027 and erode the near-term inflection point narrative.
The company’s 2026 revenue guidance of $24 million to $26 million is overly reliant on the timing of government-related development services and BARDA contract milestones, which remain opaque and execution-dependent. Management admitted they cannot disclose the revenue split between MediWound and Vericel under the BARDA contract, creating significant uncertainty about how much of the $197 million 10-year value will actually flow to MDWD. Furthermore, the guidance assumes revenue will be “weighted toward the second half” of 2026, yet Q1 2026 revenue was just $1.5 million—down from $4 million in Q1 2025—reflecting not only timing issues but also the fragility of relying on episodic government shipments postponed due to regional conflict. While Hani Luxenburg confirmed postponed shipments have been completed, this highlights the company’s vulnerability to geopolitical disruptions in its supply chain. The gross margin improvement to 21.9% (from 18.7%) was driven by a low-revenue base and does not reflect sustainable operational leverage; SG&A expenses rose to $3.6 million (from $3.1 million), and the adjusted EBITDA loss widened to $7 million (from $4 million). Without clear visibility into recurring commercial NexoBrid sales or EscharEx partnership milestones, the 2026 guidance appears aspirational rather than grounded in predictable, scalable revenue streams.
The commercialization path for EscharEx beyond venous leg ulcers remains speculative and under-substantiated, despite management’s expansion into diabetic foot ulcer (DFU) and pressure ulcer studies. While the company cited peer-reviewed consensus documents and conference presentations as validation, it provided no concrete data on efficacy, safety, or dosing regimens for these new indications during the Q&A. The planned Phase II DFU study and investigator-initiated pressure ulcer trial—both slated for H2 2026—are early-stage and carry high failure risk, particularly given the distinct pathophysiology of DFUs (e.g., neuropathy, ischemia) and pressure ulcers (e.g., sustained tissue compression). More critically, the company has not addressed how EscharEx will navigate reimbursement pathways for these indications, especially in light of the Medicare Physician Fee Schedule changes that are dismantling reimbursement for advanced wound care products broadly. Barry Wolfenson’s commentary on the $400 million SANTYL market and EscharEx’s potential to capture share assumes successful approval and adoption—but offers no insight into pricing strategy, payer negotiations, or formulary access challenges. Without clear differentiation in real-world effectiveness or cost-effectiveness data for DFU and pressure ulcers, the expansion narrative risks becoming a pipeline illusion that inflates long-term expectations without near-term de-risking, leaving investors exposed to binary outcomes tied to a single Phase III study in VLU.

Categories of related parties [axis] Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	206.44 Bn	23.61	5.42	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	179.97 Bn	-62.17	5.91	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	130.57 Bn	29.64	10.37	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	81.63 Bn	18.86	5.25	1.99 Bn
5	ARGX	Argenx Se	primary	60.34 Bn	35.18	11.55	-
6	MRNA	Moderna, Inc.	primary	54.37 Bn	-17.25	24.40	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	33.07 Bn	42.69	6.88	-
8	BIIB	Biogen Inc.	primary	31.84 Bn	38.15	3.17	8.09 Bn

MediWound MDWD

About

Investment Thesis

Categories of related parties [axis] Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password